Roche's ($RHHBY) Lucentis may have a lower retail price per prescription than competitor Eylea from Regeneron ($REGN), costing $1,471.56 to its rival's $1,408.71. But when it comes to downstream medical costs associated with the treatments? Eylea has the edge there, AdverseEvents says in a new report. In analyzing post-administration costs, AE found that the Roche treatment was significantly pricier, with adverse events costing $25.18 per prescription, versus $8.87 for Eylea. Report